You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 3
  • 186 Surgical outcome as prognostic factor in different histologic subtypes of ovarian carcinoma- analysis of 7 phase III trials by AGO Studygroup + ENGOT

Article Text

Article menu

Download PDFPDF

Ovarian cancer
186 Surgical outcome as prognostic factor in different histologic subtypes of ovarian carcinoma- analysis of 7 phase III trials by AGO Studygroup + ENGOT
Free
  1. F Heitz1,2,
  2. A Du Bois1,2,
  3. A Reuß2,3,
  4. E Pujade-Lauraine4,
  5. MR Mirza5,
  6. S Greggi6,
  7. N Colombo7,
  8. C Marth8,
  9. IB Vergote9,
  10. P Harter1,2,
  11. I Ray-Coquard10,
  12. GB Kristensen11,
  13. S Mahner2,12,
  14. AC Hardy13,
  15. J Sehouli14,
  16. P Wimberger2,15,
  17. M Eichbaum2,16,
  18. G Elser2,
  19. W Meier2,17 and
  20. J Pfisterer2,18
  1. 1Kliniken Essen-Mitte, Gynecology and Gynecologic Oncology
  2. 2AGO Study Group, Wiesbaden
  3. 3Philipps University Marburg, Coordinating Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany
  4. 4GINECO and Hôpital Dieu, Paris, France
  5. 5NSGO & Rigshospitalet, Dept. of Oncology; Copenhagen University Hospital,, Copenhagen
  6. 6MITO & Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli, Gynecologic Oncology, Naples, Italy
  7. 7MaNGO & European Institute of Oncology, Gynecologic Oncology, Milano, Italy
  8. 8AGO-A & Innsbruck Medical University, Department of Obstetrics and Gynecology, Innsbruck
  9. 9BGOG & University Hospitals Leuven, Dept. of Gynaecological Oncology, Leuven, Belgium
  10. 10GINECO & Centre Leon Bérard Université Claude Bernard Lyon Est, , Lyon , France
  11. 11NSGO & Oslo University Hospital, Oslo, Norway
  12. 12University Hospital, LMU Munich, Department of Obstetrics and Gynecology
  13. 13GINECO & Hôpital Privé des Côtes d'Armor, Plérin
  14. 14NOGGO & Charité - Universitätsmedizin Berlin, Campus Virchow, Dpt. Gynecology with Center for Oncological Surgery, Berlin, Germany
  15. 15University Hospital Essen and University Hospital Carl Gustav Carus, TU Dresden, Department of Gynecology and Obstetrics,, Dresden
  16. 16Helios Dr. Horst Schmidt Kliniken Wiesbaden, Department of Gynecology, Wiesbaden
  17. 17Düsseldorf University Hospital and Evangelisches Krankenhaus Düsseldorf, Department of Gynecology and Obstetrics, Düsseldorf, Germany
  18. 8Gynecologic Oncology Center, Kiel, Germany

Abstract

Introduction/Background*Debulking surgery is the mainstay of treatment for patients (pts) with advanced epithelial ovarian cancer (EOC). Upfront surgery (PDS) with complete macroscopic resection (TR0) is associated with best survival while PDS to small residual disease (TR1-10) provides moderate benefit in high grade serous OC. The impact of resection status in other histological subtypes so far has not been defined and especially the role of TR1-10 is under debate. This analysis should help to better understand the interplay between histological subtype, surgical outcome, and prognosis.

Methodology Data of patients (>FIGO IIIB) from 7 AGO-Studygroup led phase III multicentre trials (AGO-OVAR 3,5,7,9,11,12,15), (1995–2011) were pooled and analysed with focus on PDS resection status on overall survival (OS) in different histological subtypes: low grade (low grade serous or endometrioid), mucinous, clear cell, and high-grade (e.g. serous, endometrioid, undifferentiated histology). Multiple logistic regression of achieving TR0 in the full population and multiple Cox-regression of OS separately in each histological subpopulation adjusting potential confounders (treatment arm within each study, ECOG performance status, age, FIGO stage) were undertaken.

Result(s)*5,745 pts were eligible (5,156 high grade, 299 low grade, 219 mucinous, 71 clear cell). Differences in resection rates between histological subtypes are displayed in the table 1. Adjusted odds ratios showed significantly higher odds for achieving TR0 for low grade and clear cell compared to high-grade, (table 1). Median follow-up was 60.7 months. The figure shows OS within tumour types according to resection status. Hazard ratios between TR0, TR1-10 and TR>10 obtained from multiple Cox regression of OS are shown in the table 1.

View this table:
Abstract 186 Table 1

OR: odds ratio; OS: overall survival; HR: hazard ratio; *number of patients included into the clear cell cohort was too small to allow meaningful OS analyses

Abstract 186 Figure 1
Abstract 186 Figure 1

Kaplan-Meier plots of overall survival within tumour types according to complete (TR0) and largely (TR1-10mm) debulking; number of patients included into the clear cell cohort was too small to allow meaningful OS analyses

Conclusion*Our analysis confirmed the value of complete resection in all subtypes of ovarian cancer. The role of largely resection (TR1-10mm) seemed to be relevant in low grade OC, but marginal although significant in HGSOC and inconclusive in mucinous and clear cell OC. Larger databases are necessary to gain more reliable data in these subgroups.

https://doi.org/10.1136/ijgc-2021-ESGO.352

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.